Key Takeaways LLY will acquire Verve to add in vivo gene therapies for heart disease, including VERVE-102. Gene-editing stocks like CRSP, NTLA, and BEAM rose after the LLY-Verve deal was announced. 2025 has seen a resurgence in mergers and acquisitions targeting gene editing and rare diseases. Eli Lilly’s (LLY) recent announcement to acquire Verve Therapeutics, Inc (VERV) , a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease, has put the spotlight on other promisi ...